Therefore, the working range of both electrochemical immunosensors developed here precisely covers the critical concentration ranges for the biomarkers, showing a potential to be used as a future method for quantification of HER-1 (EGFR) and HER-2, and for the possible detection of breast cancer in patients. Here, ERBB2 is linked to breast carcinoma.